Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A prophylactic vaccine designed to provide immunity against the hepatitis B virus (HBV). In the context of the TheraVACCS clinical trial (NCT02750202) led by the University of Pretoria, this vaccine is utilized as an active control (placebo comparator) in a Phase 3 study. The trial investigates whether the quadrivalent human papillomavirus (HPV) vaccine (Gardasil) can prevent the recurrence of extensive genital warts in women following surgical treatment. The hepatitis B vaccine is administered to the control group to maintain the double-blind nature of the study while providing a health benefit (HBV protection) to the participants, although it has no known therapeutic effect on HPV-induced genital warts.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hepatitis B vaccine (University of Pretoria).